Sabrina Serani

TREASURE trial shows adding thoracic radiotherapy to atezolizumab maintenance in ES‑SCLC boosts fatal toxicity without survival gain.

Five-year WSG TP-II results suggest chemo-free endocrine therapy with dual HER2 blockade matches paclitaxel, with fewer severe side effects.

ENHANCE phase 3 results show that magrolimab added to azacitidine failed to boost remission or survival in higher-risk MDS and increased serious toxicity.

Long-term OMNIVORE follow-up shows that select advanced RCC responders stop nivolumab and remain treatment-free for years; salvage ipilimumab adds little.

Adding investigational BPM31510 to standard chemoradiation may boost survival in newly diagnosed glioblastoma, especially MGMT-unmethylated tumors, with promising safety data.

INVINCIBLE-4 restarts testing intratumoral INT230-6 before neoadjuvant pembrolizumab chemotherapy in early TNBC, aiming to boost pCR while reducing severe adverse effects.

National BRFSS study reveals SOGI adults lag in cervical and breast cancer screening; gaps are linked to insurance, access, and stigma.

Phase 3 data show TROP2 ADC sac-TMT plus pembrolizumab extends PFS in PD-L1–negative nonsquamous NSCLC, signaling a new first-line option.

Phase 3 VIKTORIA-1 results show that gedatolisib combinations extend progression-free survival in PIK3CA-mutated breast cancer, with strong response rates and manageable stomatitis.

FDA gives full approval to selpercatinib for RET fusion solid tumors, backed by 47% response rate and long-lasting benefit across cancers.

Phase 3 China trial shows B7-H3 ADC risvutatug rezetecan extends survival vs topotecan in relapsed SCLC, signaling a promising new option.

Patient-level analyses suggest DCVax-L boosts glioblastoma survival by up to 6 months, with peer review pending and no randomized control.

Eating flavonoid-rich foods such as apples, oranges, and berries is linked to lower breast cancer risk, with the biggest benefit seen in women with high genetic risk.

New study shows breast cancers within 3 years post partum score higher on Oncotype DX, reshaping risk window and treatment decisions.

KEYNOTE-355 suggests responders can pause chemo yet maintain survival on pembrolizumab; immune side effects are mostly mild and manageable.

Lung cancer increasingly hits never-smoking women; learn how biomarker testing, earlier screening, and stronger self-advocacy speed diagnosis and unlock better treatments.

TRIPLEX finds thoracic radiotherapy with durvalumab chemo in ES-SCLC adds toxicity and deaths, without boosting survival.

LAURA trial safety update shows osimertinib after chemoradiotherapy in stage III EGFR-mutant NSCLC stays manageable, no new signals.

Ateganosine (THIO) plus cemiplimab shows 90.5% disease control in heavily pretreated NSCLC in phase 2 THIO-101 trial interim data (NCT05208944).

FDA issues Complete Response Letter for manganese chloride tetrahydrate (Orviglance), an oral liver MRI contrast agent for renal-impaired patients.

Mature 13-year data show radiotherapy and temozolomide yield similar survival in low-grade glioma, but molecular subtype, not treatment order, predicts outcomes.

Virtual behavioral health embedded in community oncology boosts access for Black patients and patients on Medicaid, easing distress and improving quality of life.

Genome sequencing speeds tumor mutation discovery, boosting targeted cancer therapies and cell/gene treatments while raising urgent questions about data ownership, reporting uncertainty, and ethics.

Data link food deserts to metastatic breast cancer mutations and shorter survival, urging oncologists to screen for food insecurity.

FDA issues CRL for Ga-68 edotreotide NET PET kit, citing third-party manufacturing; decentralized SSTR imaging promise remains pending.

FDA clears BESREMi Pen, adding a simpler self-injection choice for adults with polycythemia vera on long-term ropeginterferon therapy.

TRIDENT shows early TTFields with chemoradiation doesn’t boost survival in newly diagnosed glioblastoma, but remains feasible with stable safety.

MammaPrint in the FLEX registry predicts which HR+/HER2– early breast cancers benefit from anthracyclines—guiding safer, personalized chemo.

Myriad’s Precise MRD expands to breast, colorectal and renal cancers, using serial ctDNA tracking to spot residual disease and predict response.

FDA approves sacituzumab govitecan-hziy alone or with pembrolizumab as first-line therapy for unresectable/metastatic triple-negative breast cancer.